Rani Therapeutics enters exclusive worldwide license with Celltrion for oral adalimumab biosimilar

Rani Therapeutics Holdings, Inc.

Rani obtains exclusive, worldwide, royalty-free license to Celltrion IP for oral adalimumab biosimilar via Rani's delivery technology.
Celltrion will exclusively supply adalimumab biosimilar to Rani, with limited alternative sourcing rights if supply is disrupted.
Rani has sole manufacturing, development, and commercialization rights; Celltrion gets right of first negotiation after Phase 1 data.
Celltrion may terminate if development milestones not met; Rani can terminate for convenience with notice.
No financial terms disclosed; agreement covers IP ownership and mutual indemnification.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rani Therapeutics Holdings, Inc. entered into License and Supply Agreement with Celltrion, Inc. valued at Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product; (effective 2023-06-01).

Action: entry
Agreement: license
Counterparty: Celltrion, Inc.
Value: Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product;
Effective: 2023-06-01

Exact text from the filing

On June 1, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”). Under the License Agreement, Celltrion grants Rani an exclusive, worldwide, royalty-free license to certain intellectual property to make, use, sell, offer for sale, import and otherwise exploit an orally-administered therapeutic product using Rani’s oral delivery technology and Celltrion’s adalimumab biosimilar (“Product”) and to use certain information to support the manufacture, development and commercialization of Product.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-026234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.